Skip to main content
SpringerLink
Log in

SEOM clinical guidelines for the treatment of thyroid cancer

  • Clinical Guides in Oncology
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Although thyroid cancer represents less than 1% of malignant tumours, its increased incidence detected in recent years and the appearance and development of new drugs targeting specific molecular targets has attracted the attention of the doctors involved in this pathology, especially medical oncologists. For this reason it is important at this critical point, when treatment may be substantially changed, to establish and agree updated guidelines. These guidelines should incorporate the newly developed strategies that, although still preliminary in evidence level, will surely have an important role, especially in relapsed and refractory tumours, which are unsuitable for surgical or radio-iodine treatment. Particular histological and molecular features of these tumours must be taken into account in order to optimise therapeutic approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295:2164–2167

    Article  PubMed  CAS  Google Scholar 

  2. National Cancer Institute Web site. Thyroid Cancer. http://seer.cancer.gov/statfacts/html/thyro.html. Accessed 06/04/08

  3. Davidson BJ, Burman KD (2003) Cancer of thyroid and parathyroid. In: Harrison LB, Sessions RB, Hong WK et al (eds) Head and neck cancer: a multidisciplinary approach. Wolters Kluwer/Lippincott, Philadelphia, PA

    Google Scholar 

  4. Edge SB, Byrd DR, Compton CC et al (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York, pp 87–96

    Google Scholar 

  5. Robbins RJ. Wan Q, Grewal RK et al (2006) Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucosepositron emission tomography scanning. J Clin Endocrinol Metab 91:498–505

    Article  PubMed  CAS  Google Scholar 

  6. National Comprehensive Cancer Network (2007) Clinical practice guidelines in oncology. Thyroid carcinoma, V.2.2007. AJCC 6th edn. www.nccn. org/professionals/physician_gls/PDF/thyroid.pdf

  7. Carling T, Udelsman R (2005) Thyroid tumors. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott, Williams and Wilkins, Philadelphia, pp 1502–1520

    Google Scholar 

  8. Sherman SI, Tutle RM, Ball DW et al (2008) NCCN practice guidelines for thyroid carcinoma. NCCN, www.nccn.org

  9. Staunton MD (1994) Thyroid cancer: a multivariate analysis on influence of treatment on long-term survival. Eur J Surg Oncol 20:613–621

    PubMed  CAS  Google Scholar 

  10. Jonklaas J, Sarlis NJ, Litofsky D et al (2006) Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16:1229–1242

    Article  PubMed  Google Scholar 

  11. McGriff NJ, Csako G, Gourgiotis L et al (2002) Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 34:554–564

    Article  PubMed  CAS  Google Scholar 

  12. Shimaoka K, Schoenfeld D, DeWys WD et al (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155–2160

    Article  PubMed  CAS  Google Scholar 

  13. Cohen EW, Rosen LS, Vokes EE (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708–4713

    Article  PubMed  CAS  Google Scholar 

  14. Gupta-Abramson V, Troxel AB, Nellore A (2008) Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714–4719

    Article  PubMed  CAS  Google Scholar 

  15. Kloos RT, Ringel MD, Knopp MV et al (2009) Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675–1684

    Article  PubMed  CAS  Google Scholar 

  16. Sherman SI, Wirth LJ, Droz JP et al (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Eng J Med 359:31–42

    Article  CAS  Google Scholar 

  17. Cohen EE, Needles B, Cullen K et al (2008) Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 26:abstr 6025

    Google Scholar 

  18. Ravaud A, de la Fouchardiere C, Courbon F et al (2008) Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol 26:abstr 6058

    Article  Google Scholar 

  19. Ain KB, Lee C, Williams KD (2007) Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 17:663–670

    Article  PubMed  CAS  Google Scholar 

  20. Orlandi F, Caraci P, Berruti A et al (1994) Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol 5:763–765

    PubMed  CAS  Google Scholar 

  21. Wu LT, Averbuch SD, Ball DW et al (1994) Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73:432–436

    Article  PubMed  CAS  Google Scholar 

  22. Cohen EW, Rosen LS, Vokes EE (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708–4713

    Article  PubMed  CAS  Google Scholar 

  23. Cohen EE, Needles B, Cullen K et al (2008) Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 26:abstr 6025

    Google Scholar 

  24. Hadadd R, Krebs A, Vasselli J et al (2008) A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 26:abstr 6024

    Google Scholar 

  25. Wells SA, Gosnell JE, Gagel RF et al (2007) Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. J Clin Oncol 25:303s

    Google Scholar 

  26. Schlumberger MJ, Elisei R, Bastholt L et al (2009) Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794–3801

    Article  PubMed  CAS  Google Scholar 

  27. Lam ET, Ringel MD, Kloos RT et al (2010) Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28:2323–2330

    Article  PubMed  CAS  Google Scholar 

  28. Wells SA Jr, Robinson BG, Gosnell et al (2010) Vandetanib in locally advanced or metastasic medullary thyroid cancer: a randomized double blind Phase III trial (ZETA). J Clin Oncol 28:15s

    Article  Google Scholar 

  29. Lang BH, Lo CY (2007) Surgical options in undifferentiated thyroid carcinoma. World J Surg 31:969–977

    Article  PubMed  Google Scholar 

  30. Lim S, Lee NY, Fury MG et al (2007) Doxorubicin and concurrent radiotherapy for anaplastic thyroid cancer: we need to do better. J Clin Oncol 25:669s

    Article  Google Scholar 

  31. Tennvall J, Lyndell G, Wahlberg P et al (2002) Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 86:1848–1853

    Article  PubMed  CAS  Google Scholar 

  32. Cooney M, Savvides P, Agarwala S et al (2006) Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). J Clin Oncol 24:abstr 5580

    Google Scholar 

  33. Tuttle RM, Ball DW, Byrd D et al (2010) National Comprehensive Cancer Network. Thyroid carcinoma. J Natl Compr Canc Netw 8:1228–1274

    PubMed  Google Scholar 

  34. Kloos RT, Eng C, Evans DB et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565–612. Review. Erratum 19:1295

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Oncología Médica, Hospital Universitario Miguel Servet, P. de Isabel la Católica, 1-3, ES-50009, Zaragoza, Spain

    Javier Martínez Trufero

  2. Servicio de Oncología Médica, Hospital Vall d’Hebron, Barcelona, Spain

    Jaume Capdevilla

  3. Servicio de Oncología Médica, Hospital Universitario Salamanca, Salamanca, Spain

    Juan Jesús Cruz

  4. Servicio de Oncología Médica, Hospital Lozano Blesa, Zaragoza, Spain

    Dolores Isla

Authors
  1. Javier Martínez Trufero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaume Capdevilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juan Jesús Cruz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dolores Isla
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Javier Martínez Trufero.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martínez Trufero, J., Capdevilla, J., Cruz, J.J. et al. SEOM clinical guidelines for the treatment of thyroid cancer. Clin Transl Oncol 13, 574–579 (2011). https://doi.org/10.1007/s12094-011-0700-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-011-0700-3

Keywords

Search

Navigation